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ABSTRACT
Endogenous Cushing’s Syndrome (CS) is unusual. Patients with subclinical CS
(SCS) present altered cortisol dynamics without obvious manifestations. CS
occurs in 2–3% of obese poorly controlled diabetics. We studied 103 over-
weight adult outpatients with type 2 diabetes to examine for cortisol abnor-
malities and SCS. All collected salivary cortisol at 23:00 h and salivary and
serum cortisol after a 1 mg dexamethasone suppression test (DST). Patients
whose results were in the upper quintile for each test (253 ng/dL, 47 ng/dL, and
1.8 µg/dL, respectively for the 23:00 h and post-DST saliva and serum cortisol)
were re-investigated. Average values from the upper quintile group were 2.5-
fold higher than in the remaining patients. After a confirmatory 2 mg x 2 day
DST the investigation for CS was ended for 61 patients with all normal tests
and 33 with only one (false) positive test. All 8 patients who had two abnormal
tests had subsequent normal 24h-urinary cortisol, and 3 of them were likely to
have SCS (abnormal cortisol tests and positive imaging). However, a final diag-
nosis could not to be confirmed by surgery or pathology. Although not confir-
matory, the results of this study suggest that the prevalence of SCS is consid-
erably higher in populations at risk than in the general population. (Arq Bras
Endocrinol Metab 2007;51/7:1118-1127)
Keywords: Type 2 diabetes mellitus; Obesity; Overweight; Hypercortisolism;
Cushing’s syndrome; Subclinical Cushing’s syndrome
RESUMO
Aumento da Probabilidade Diagnóstica de Síndrome de Cushing
Subclínica em uma Amostra Populacional de Pacientes Adultos
Obesos com Diabetes Mellitus Tipo 2.
A síndrome de Cushing (SC) endógena é rara. Pacientes com SC subclínica
(SCS) apresentam hipercortisolismo sem manifestações clínicas. SC ocorre em
2–3% de diabéticos mal controlados. Estudamos 103 pacientes adultos obesos
ambulatoriais com diabetes mellitus tipo 2 para avaliar alterações do cortisol e
SCS. Todos coletaram cortisol salivar às 23:00 h e cortisol salivar e sérico após
teste de supressão com 1 mg de dexametasona (DST). Pacientes cujos resul-
tados de qualquer teste estavam no quintil superior (253 ng/dL, 47 ng/dL e 1,8
µg/dL, respectivamente para cortisol salivar 23:00 h e salivar e sérico pós-DST)
foram reavaliados. Os valores médios desse grupo encontravam-se 2,5 vezes
acima dos valores dos demais pacientes. Após um teste confirmatório com 2
mg x 2 dias DST, a investigação da SC foi encerrada para 61 pacientes com
todos os testes normais e 33 com apenas um teste (falso) positivo. Todos os 8
pacientes com dois testes alterados apresentaram cortisol urinário normal,
mas 3 deles mostraram maior probabilidade diagnóstica de SCS (hipercorti-
solismo e alterações em exames de imagem). Contudo, o diagnóstico final não
pode ser confirmado por cirurgia ou patologia em nenhum deles. Embora não
confirmatórios, os resultados deste estudo sugerem que a prevalência de SCS
seja maior em populações de risco do que na população geral. (Arq Bras
Endocrinol Metab 2007;51/7:1118-1127)
Descritores: Diabetes mellitus tipo 2; Obesidade; Sobrepeso; Hipercortisolis-
mo; Síndrome de Cushing; Síndrome de Cushing subclínica
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THE WIDESPREAD USE OF POTENT synthetic gluco-corticoid for a number of medical conditions is
often associated with florid “cushingoid” manifesta-
tions. However, endogenous hypercortisolism or
Cushing’s syndrome (CS) is considered an unusual
disorder (1).
Endogenous CS is due either to primary
(adrenal) or secondary (hypothalamic-pituitary) caus-
es, the most common of which (80%) is “Cushing’s
disease”, resulting from a corticotropin-secreting pitu-
itary microadenoma. The cortisol-secreting adrenal
adenoma, the second most common cause of CS,
responds for less than 10% of the cases, although
recent findings in reported series of adrenal inciden-
talomas point to a novel medical condition referred to
as “subclinical CS” (3). In this setting, mildly altered
cortisol dynamics is not associated with obvious clini-
cal manifestations. In contrast, the metabolic syn-
drome resembles CS in several clinical aspects, but
shares only a few abnormalities in cortisol dynamics.
The incidence of CS is estimated in 1:50,000 to
1:100,000 inhabitants of a general population (1,2).
However, the metabolic syndrome (4) as well as the
adrenal incidentaloma (2) has been reported increas-
ingly worldwide.
Thus, it is conceivable that the incidence of CS
could be higher than previously reported, provided
screening tests are aimed at specific populations at risk.
In fact, Leibowitz et al. (5) and Catargi et al. (6)
found incidences of 2.2% and 2% in respectively 153
and 200 obese poorly controlled diabetic patients.
Screening tests for the diagnosis of CS include:
(1) late-night (23:00 h) serum or saliva cortisol (to
examine the absence of a circadian rhythm), (2) response
to 1 mg overnight dexamethasone suppression (to assess
corticotroph resistance to the negative feedback), and
(3) 24h-urinary free cortisol excretion rate (an indirect
estimation of increased cortisol production) (6).
The former two tests are likely to be more sensi-
tive in the detection of subclinical CS, in contrast to
increased urinary free cortisol, that may be elevated only
when clinical manifestations are present. Using appro-
priate cut-off values for greatest specificity, the sensitiv-
ity of these tests is generally acceptable to establish them
as diagnostic standards for screening (7).
In CS, the frequency of obesity, glucose intol-
erance (with or without overt diabetes mellitus), and
arterial hypertension reaches up to 90% of the patients
(8-12). Nonetheless, each of these three features is
highly prevalent worldwide (13-15).
Although mortality is already elevated in obese,
diabetic, and/or hypertensive patients, it may be even
higher in those with CS. When matched for age and
gender, mortality of patients with SC was shown to be
4-fold higher than in the general population, mostly
due to cardiovascular disease (16,17).
Medical and surgical cure or remission of the
excess cortisol state in clinical or subclinical CS (adren-
al incidentalomas) is associated with reduction in body
mass and with significant improvement in glucose con-
trol and blood pressure levels (17,18).
In this paper we investigate adult overweight
patients with type 2 diabetes mellitus (DM2) routine-
ly followed in the Diabetes Clinic of our Institution, to
verify the extent and magnitude of the abnormalities
in cortisol dynamics and, as a consequence, if patients
may have undiagnosed or occult CS, that could bene-
fit from proper treatment.
PATIENTS AND METHODS
We examined the medical charts of 285 sequential outpa-
tients with DM2 who have been routinely followed in the
Diabetes Center of the Division of Endocrinology at the
Federal University of São Paulo, SP, Brazil. The diagnosis of
DM2 has been previously established in all by current clini-
cal, laboratory, and immunologic standards (19,20).
Patients with the following criteria were excluded:
(1) younger than 20 years of age, (2) BMI below 25 kg/m2,
(3) pregnancy and breast-feeding, (4) previous or ongoing
diagnosis of endogenous Cushing’s syndrome, depression,
chronic renal, and/or hepatic insufficiency, and alcoholism,
and (5) use of drugs that could potentially interfere with the
diagnostic tests or laboratory assessment of cortisol, such as
glucocorticoids, rifampicin, ketoconazole, carbamazepine,
desmopressin, and mifepristone.
Of the 285 patient charts examined, 125 (44%) ful-
filled the inclusion criteria and patients were summoned for
a preliminary interview. One hundred and three of them
(82.4%) — 69 female and 34 male, ranging from 36 to 82
years of age (median of 56) — agreed to participate in the
protocol that had been previously approved by the Ethics
Committee on Human Research from our Institution.
On a separate appointment, all 103 patients signed a
written consent and were officially enrolled, having the fol-
lowing clinical and physical examination data compiled: time
from initial diagnosis of DM2 and hypertension, if present,
weight and height, waist and hip circumferences (to calculate
the waist:hip ratio – WHR), arterial blood pressure (BP), and
medicines being used. Recent routine laboratory tests (within
the last 30 days) were assembled, in special serum glucose, gli-
cated haemoglobin (HbA1c), total and fractionated choles-
terol, total blood count, creatinine, and urinalysis.
All patients were told to maintain their regular activities
and routine medicines and to remain fast after 22:00 h on a
specified day. At 23:00 h of that day they were instructed to
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collect saliva in a specific collector (Salivette®, Sarstedt, Ger-
many) after oral hygiene with filtered water, and to keep the
material under refrigeration until the next morning. Immedi-
ately after the saliva collection they should take 1 mg dexam-
ethasone (DEX, 2 x 0.5 mg Decadron® tablets, Prodome,
Brazil) with half a glass of water. The next morning all patients
were seen in the laboratory where they had blood and a second
saliva sample drawn between 08:00 h and 09:00 h.
Free cortisol was measured in the saliva and total
serum cortisol, DEX and glucose in the blood samples.
Although serum DEX was initially assessed to confirm inges-
tion and to validate the 1 mg overnight DEX suppression
test (DST), its levels were subsequently used for correlation
purposes.
Instead of using pre-established test cut-off values for
selecting patients at risk for CS, we chose to call back every
patient whose test results were within the upper quintile
(P80) for each test. This procedure introduces a higher sen-
sitivity and would permit the investigation of a greater num-
ber of suspicious patients, in especial those who were in the
“grey zone” for dynamic tests.
Additional testing / further investigation
Except for six patients (3M/3F) who subsequently declined
additional testing, all other 23 who did not suppress saliva
(values ≥ 47 ng/dL) and/or serum cortisol (values ≥ 1.8
µg/dL) levels following a valid 1 mg overnight DST (serum
DEX > 157 ng/dL at 08:00 h, see below), and regardless of
the 23:00 h saliva cortisol level, were summoned for further
investigation. An additional test was then performed, con-
sisting of the classic low-dose DST (0.5 mg DEX PO every
6h for 8 doses) (21) in which blood samples were drawn
before and 48 h later for serum cortisol and DEX.
From this point on, and despite the exclusive
response to the classic low-dose DST, patients who had two
abnormal test responses (elevated 23:00 h saliva cortisol and
non-suppressible saliva or serum cortisol in response to
either the 1 mg overnight or the 2 mg DST) proceed to fur-
ther investigation for CS, which included: (a) measurement
of plasma ACTH, (b) dehydroepiandrosterone sulfate
(DHEAS), (c) a 24h-urinary free cortisol, and (d) a DDAVP
stimulation test (DDAVP®, 8 µg IV bolus, Ferring, Swe-
den), in which ACTH and cortisol were measured every 15
min for 2 h (21,22). Finally, all patients had an adrenal
imaging performed with fine-cut computerized tomography
(CT) scans and a pituitary magnetic resonance imaging.
Figure 1 illustrates the algorithm used to investigate
CS in this particular at-risk population sample.
Assays
Saliva material was centrifuged at 2,000 rpm and together
with serum samples was kept frozen until the respective assays.
Salivary cortisol was measured in 25 µl saliva aliquots by an in-
house radioimmunoassay (RIA) without previous extraction
or chromatography, as previously described (23). In brief, the
intra- and interassay coefficients of variation were 4.4% and
5.1%, respectively, with a detection limit of 10 ng/dL.
Serum cortisol was measured by an in-house RIA
(24,25). Serum DHEAS and plasma ACTH were also deter-
mined by commercially available chemiluminescent
immunometric assay kits (Immulite® 2000 DPC, USA) and
urinary cortisol by a RIA kit (DSL-2100 Active® cortisol,
USA). Serum DEX was measured by an in-house RIA as fol-
lows: 50 µl of serum was added to rabbit anti-DEX antibod-
ies (kindly provided by Dr. José Gilberto Vieira, Fleury Lab-
oratory), and 3H-DEX tracer (Amersham, USA), and then
incubated at 4ºC for 12–16h. The tracer-antibody reaction
was interrupted, free antibodies were separated with dextran-
charcoal and radioactivity was measured in the supernatant
with a β-counter. Intra- and interassay CV are 6.3% and
6.0%, respectively, with the limit of sensitivity for that
method set at 20 ng/dL.
For statistical purposes all values below the limit of sen-
sitivity for the particular assay were arbitrarily considered equal
to the detection value divided by the square root of 2 (26).
Screen tests cut-offs
The P80 cut-off or threshold values (that separate patients in
the upper quintile) for each screening test were, respective-
ly: 253 ng/dL, 47 ng/dL, and 1.8 µg/dL, for the 23:00 h
and the post-1 mg DST saliva, and the post-1 mg serum cor-
tisol. The same 1.8 µg/dL threshold value was used for the
post-2 mg DST.
Of note, these cut-offs values were close or similar to
those previously reported to separate patients suspected to
have CS from normal controls: 200 ng/dL (27) and 62
ng/dL (28), respectively for the late-night (23:00 h) and
post-1 mg overnight DST saliva, and 1.8 µg/dL for the
overnight 1 mg (22) as well as for the low-dose (2 mg x 2 d)
DST.
Therefore, for the purposes of the present study we
considered saliva and cortisol levels that were equal or high-
er than the P80 threshold as “positive test results” for hyper-
cortisolism.
The overnight 1 mg and the 2 mg x 2 d DST were
validated whenever 08:00 h post-test serum DEX levels were
> 157 ng/dL (95% CL).
Statistical analysis
Comparison between variables was performed using the
Mann-Whitney U test and Student’s t test, where appropri-
ate. Correlation coefficients were determined by the Spear-
man test. The level of statistical significance was set at 5% (p
< 0.05).
RESULTS
Clinical characteristics of the population
sample (table 1)
Age, duration of DM2, BP, weight, BMI, WHR, and
HbA1c from the 103 patients studied are presented in
table 1, according to gender. Male and female patients
Cushing’s Syndrome Among Overweight DM2
Caetano, Silva & Kater
1121Arq Bras Endocrinol Metab 2007;51/7
Table 1. Clinical characteristics of the 103 patients studied, according to gender.
Total of patients (n = 103; 34M/69F)
Mean ± SD Median [range]
Age (y) 56.4 ± 8.8 56 [36–82]
Duration of DM (y) 10.8 ± 7.5 9 [1–40]
BP (mmHg): Systolic 149.5 ± 23.2 150 [110–220]
Diastolic 92.3 ± 13.9 90 [70–130]
Weight (kg): M 85.7 ± 16.3 80.1 [65.9–132]
F 75.7 ± 12.2* 74.0 [51.5–110]
BMI (kg/m2): M 30.5 ± 5.1 28.7 [25.0–43.6]
F 31.7 ± 4.7 31.4 [25.1–48.9]
Waist circumfer. (cm): M 102.4 ± 12.0 99 [83–134]
F 100.5 ± 11.2 100 [72–136]
WHR: M 0.99 ± 0.05 0.99 [0.82–1.09]
F 0.95 ± 0.07** 0.95 [0.78–1.16]
HbA1c (%): M 7.8 ± 1.6 7.6 [5.3–12.0]
F 9.0 ± 2.3* 9.3 [5.1–15.6]
* P < 0.01, M vs. F (Mann-Whitney’s test)
** P < 0.005, M vs. F (Student’s t test)
Patients enrolled
(n=103)
All normal
(n=61)
Normal
(n=15)
Normal, but...
Confirmatory testing: 24h-urinary free cortisol, plasm
ACTH, DHEAS, Adrenal CT, Pituitary MR imaging
Abnormal
(n=1)
* 1 mg Overnight DST is validated if serum DEX concentration > 157 ng/dl
...23:00H saliva
ande 1 mg DST
abnormal (n=7)
Investigation
terminated
Confirmatory test
2mg x 2d DST (n=23)
Only 23:00 saliva
abnormal (n=12)
1mg Overnight DST
abnormal (n=29)
Declined further
investigation
Only saliva (n=9)
or serum (n=9)
Both (n=11)
Invalid test (n=1)
Screening tests for hypercortisolism: 23:00h
saliva + 1mg overnight DST (salica and/or serum)
Figure 1. Algorithm used in the present series to screen overweight adult patients with DM2 for
Cushing’s syndrome.
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did not differ regarding age, duration of DM2, BMI,
and waist circumference, although weight and the
WHR were significantly higher in men.
Most of the patients (81.5%, being 79.4% male
and 82.6% female) were already hypertensive at the
beginning of the study; even on treatment the average
systolic and diastolic BP were still elevated. Duration
of hypertension varied from 1 to 41 years (median of
10). HbA1c was significantly higher in women.
Hormonal values (table 2)
Saliva (23:00 h and post-1 mg DST) and serum corti-
sol (post-1- and post-2 mg DST) values are presented
in table 2 as mean (± SD) and median (range), as well
as the P80. As previously defined, values ≥ P80 (upper
quintile) for each test were considered “suspicious” for
diagnostic purposes, in contrast to the “normal” ones
(below the P80 value). In the upper quintile group,
23:00 h and post-1 mg DST saliva cortisol values
ranged from 253 to 527, and 47 to 117 ng/dL,
respectively, whereas post-1 mg DST serum cortisol
ranged from 1.8 to 7.8 µg/dL (figure 2). Average val-
ues from the upper quintile group were approximately
2.5- to 3-fold higher than in the remaining 80% of
patients. When patients in the upper quintile group
were compared to the remaining ones for any of the
three tests, there were no significant differences
regarding age, BMI, waist circumference, WHR, and
HbA1c. However, systolic and diastolic BP were sig-
nificantly higher in the upper quintile group.
Since DM has been occasionally associated to
abnormalities in the HHA axis, we compared the results
of saliva and serum cortisol to serum glucose or HbA1c
levels and found no correlation with the test results.
Because the serum cortisol cut-off of 1.8
µg/dL used for the 1 mg DST in the present study
was similar to the value used systematically in the lit-
erature, we compared serum and saliva cortisol
responses to 1 mg DST using a 2 x 2 table: results
were concordant in 84 patients (73 did suppress
serum cortisol below 1.8 µg/dL and saliva cortisol
below 47 ng/dL, whereas 11 did not), and were dis-
cordant in 18, nine “false-positives’ and nine “false-
negatives” (figure 3).
Therefore, when the cut-off value of 47 ng/dL
was used to define a positive response for the 1 mg
DST saliva cortisol, as compared to the 1.8 µg/dL
serum cortisol, we obtained a sensitivity of 57.1% and
a specificity of 89% for this test. Even with such a small
sensitivity this value is already clearly below values used
by others (28).
Validation of the DST was ascertained by mea-
suring concurrently obtained serum DEX levels at
08:00 h. Serum DEX levels ranged from 135 to 761
ng/dL (mean ± SD of 346 ± 122; median of 340).
Using a cut-off value for “positive” DEX levels set at
157 ng/dL (95% CI), only one (out of 103) 1 mg
DST was considered invalid and therefore excluded
from statistical analysis. The 2 mg x 2 d DST was not
validated (DEX < 157 ng/dL) in 3 of 4 patients who
did not suppress serum cortisol levels; a normal and
valid response was obtained in 19 (82.6%) patients.
Table 3 shows the clinical data of patients sub-
grouped according to test results: 61 patients (25%M/
75%F) had all 3 tests normal, 33 had only one (either
a 23:00 h saliva cortisol [n = 12] or a post-1 mg DST
saliva or serum cortisol [n = 21]) and eight had two
abnormal test responses.
Table 2. Mean (± SD), median (P50, and range), and P80 values of cortisol determinations
in saliva (23:00 h and 08:00 h after 1 mg DST) and serum (after 1 mg and 2 mg DST).
Mean ± SD P50 or Median [range] P80
23:00 h Saliva (n = 103) 172.3 ± 101.9 154 [29.5–527.1] 253  
≥ P80 339.9 ± 77.6    
< P80 129.3 ± 49.4    
1 mg Overnight DST      
Saliva (n = 102)* 30.4 ± 24.1 26.8 [7–117] 47  
≥ P80 69 ± 22.6    
< P80 21 ± 12.1     
Serum (n = 102)* 1.4 ± 0.9 1.2 [0.4–7.8] 1.8  
≥ P80 2.6 ± 1.4    
< P80 1.1 ± 0.3    
2 mg x 2 day DST (n = 20)# 0.9 [0.3–2.6] 1.8  
≥ P80 (n = 1) 2.6    
< P80 (n = 19) 0.8 ± 0.4    
* One and # Three false-positive tests were excluded (invalid).
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Patients with likely “endogenous hypercor-
tisolism”
Eight patients (4M/4F) had a tentative diagnosis of
endogenous hypercortisolism made, due to a combi-
nation of elevated 23:00 h saliva cortisol levels, and
non-suppressible saliva or serum cortisol levels to 1 mg
and/or 2 mg DST.
Individual clinical data and hormonal results for
these eight patients are depicted in table 4. In all, a
subsequent 24h-urinary free cortisol sample gave nor-
mal results, whereas basal plasma ACTH levels were
subnormal (< 10 pg/mL) in one (with serum DHEAS
also subnormal), low-normal (10–20 pg/mL) in five
(with serum DHEAS subnormal in one) and > 20
pg/mL in two (both with normal DHEAS).
ACTH was unresponsive to a DDAVP stimula-
tion test in six, four of whom had normal pituitary MR
and adrenal CT imaging (table 4).
Four patients were diagnosed as having bilater-
al adrenal hyperplasia (BAH) on adrenal CT, one of
23:00h Saliva 1 mg DST Saliva 1 mg DST Serum
600
ng/dl
500
400
300
200
100
0
120
ng/dl
100
80
60
40
20
0
9.0
µg/dl
7.5
6.0
4.5
3.0
1.5
0
≥ P80 (5th quintile) < P80 (“normal”)
Figure 2. Saliva and serum cortisol levels in adult overweight
DM2 patients evaluated for Cushing’s syndrome. The shaded
areas include values from patients who were in the upper
quintile for each screening test (above the P80 thresholds that
were respectively: 253 ng/dL, 47 ng/dL, and 1.8 µg/dL, for the
23:00 h and the post-1 mg DST saliva, and the post-1 mg DST
serum cortisol). Values in the shaded areas were considered
suspicious for endogenous hypercortisolism.
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Figure 3. Correlation of concurrent serum and saliva cortisol
levels after 1 mg DST. Individual pairs of post-DST serum and
saliva cortisol levels were concordant in 84 patients (placed
in the upper right and the lower left quadrants).
Table 3. Clinical characteristics of the overweight diabetic patients grouped according to their responses to the functional tests for Cushing’s syndrome: all normal (n =
61), one (n = 33) and two (n = 8) abnormal tests.
All normal (n = 61) One abnormal test (n = 33) Two abnormal tests (n = 8)
Salivary cortisol 23:00 Salivary or serum cortisol
h (n = 12) post-1 mg DST (n = 21)
Mean Median Mean Median Mean Median Mean Median
Age (y) 55.8 ± 8 56 [38–75] 54.3 ± 9.4 53.5 [42–67] 59.5 ± 8.8 58 [43–82] 53.3 ± 10.3 55.5 [36–67]
Years of DM 10.7 ± 7.7 9 [2–40] 11.8 ± 7.6 9 [3–26] 11.0 ± 6.2 11 [2–22] 10.1 ± 10.1 7 [1–34]
Weight (kg) 78.1 ± 14.2 75.8 [51.5–110.5] 78 ± 13.6 75.6 [61.3–112.6] 81.9 ± 15.4 79.8 [63.5–132] 82.1 ± 15.2 76.9 [67.8–115.4]
BMI (kg/m2) 31.3 ± 4.9 30.3 [25–48.9] 31.4 ± 4.9 30.3 [25.7–40.9] 31.7 ± 4.9 30.8 [25.7–43.6] 31.2 ± 4.4 30.9 [25.5–38.1]
Waist (cm) 100.9 ± 11.2 101 [80–136] 102.9 ± 7.6 101 [92–120] 101.5 ± 13.0 99 [83–104] 102.5 ± 10.8 99 [91–124]
WHR 0.96 ± 0.07 0.96 [0.78–1.11] 0.97 ± 0.05 0.98 [0.87–1.06] 0.96 ± 0.08 0.98 [0.82–1.16] 0.97 ± 0.06 0.98 [0.89–1.04]
SBP (mmHg) 145.9 ± 21.5 140 [110–200] 142.5 ± 20.9 135 [120–180] 160 ± 22.8 160 [130–210] 160 ± 32.1 155 [120–220]
DBP (mmHg) 89.7 ± 11.2 90 [70–110] 88.3 ± 15.3 90 [70–110] 100.5 ± 16 100 [80–130] 96.3 ± 18.5 100 [70–120]
HbA1c (%) 8.7 ± 2.3 8.4 [5.1–15.6] 8.3 ± 1.5 8.8 [5.3–9.9] 8.8 ± 1.8 9.4 [6.0–12.5] 7.8 ± 2.7 6.9 [6.2–14.4]
Glicemia (mg/dL) 151.2 ± 74 132 [53–488] 135.5 ± 49.7 122 [58–223] 158 ± 56.9 144 [93–365] 134.5 ± 40.7 128 [74–192]
23:00 h Saliva 122.5 ± 46.5 117 [30–212.1] 325.9 ± 76.7 299.4 [253–512] 149.2 ± 53.4 156 [29.5–232.7] 367.3 ± 79.9 370.5 [264–527.1]
F (ng/dL)
1 mg-DST 20.2 ± 11.8 17.5 [7–46] 18.5 ± 14 13 [7–46] 54.1 ± 23.9 49 [16–105] 63.8 ± 34 58.3 [20.1–117]
Saliva (ng/dL)
1 mg-DST 1.1 ± 0.3 1.1 [0.4–1.7] 1.1 ± 0.4 1.2 [0.4–1.7] 1.9 ± 0.6 1.9 [1.1–3.2] 3.1 ± 2.2 2.4 [1.3–7.8]
Serum (µg/dL)
DEX (ng/dL) 348.2 ± 128.5 339 [140–761] 333.4 ± 135.2 345 [159–660] 359.7 ± 96 356 [165–514] 311.4 ± 126.9 314 [135–476]
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whom with an additional 0.8 cm left adrenal nodule:
one with an empty sella, one with a 5–6 mm sellar
nodule, and two with normal pituitary MR imaging.
The overall analysis of plasma ACTH, urinary
free cortisol, serum DHEAS, and DDAVP stimulation
test, together with negative adrenal and pituitary
imaging, made the probability of diagnosing CS in five
of those eight patients rather slim.
The final three patients (# B, D, and H, in table
4) were likely to have subclinical CS, but in none this
diagnosis could be surgically and/or pathologically
confirmed so far. Patient B has bilateral adrenal hyper-
plasia (BAH) and an adrenal nodule, ACTH > 20
pg/mL and a positive response to DDAVP, but has an
unremarkable pituitary MR imaging. Although this
may occur in up to 40% of patients with Cushing’s dis-
ease (29,30), she declined inferior petrosal sinus sam-
pling (IPSS) and has been followed clinically ever
since.
Patient H has BAH with a 6 mm pituitary nod-
ule identified by MR. He also declined IPSS and sub-
sequent surgery, if ever indicated.
Patient D is the most likely to present CS: she
has BAH with an empty sella, repeatedly non-sup-
pressible serum cortisol levels, but undetectable and
DDAVP-unresponsive ACTH values. Partial investiga-
tion for macronodular adrenal hyperplasia resulted
inconclusive, and a definite diagnosis could not yet be
established.
DISCUSSION
Among the classical manifestations of cortisol excess in
CS, central obesity, glucose intolerance, and arterial
hypertension predominate. These features are also char-
acteristic of the metabolic syndrome, a highly prevalent
condition among the general population. The elevated
mortality observed in patients with CS is not only asso-
ciated to cardiovascular events (16,17), but also to the
period of exposure to cortisol excess (31).
Adult overweight type 2 diabetic patients, as in
the case of the present study, also have a high preva-
lence of hypertension, being a distinctive risk group
for the occurrence of CS.
The algorithm applied to investigate the extent
and magnitude of cortisol abnormalities (figure 1) was
a logical one in trying to screen and uncover patients
who may have occult or undiagnosed CS. Using late-
night saliva followed by the 1 mg overnight DST, and
measuring serum and saliva cortisol the next morning,
we were able to exclude almost 60% of the patients in
whom all results came back normal (below the P80
cut-off value for each test). By doing this we restricted
the investigation to the most suspicious upper quintile
subgroup, running only a minor risk of missing
patients with CS but with false-negative results. In
addition, because 23:00 h saliva cortisol was consid-
ered the least robust among the screening procedures
(28), we also excluded 12 additional patients in whom
this was the only abnormal result, raising to 72% the
total of patients initially excluded.
Except for post-DST saliva cortisol, the thresh-
old values established in the present series — by choos-
ing the P80 value for each test — were close or even
similar to those reported in the literature, that were
most likely defined by ROC curves. Values for the
08:00 h saliva cortisol after overnight DST have been
previously reported by Castro et al. (28), who defined
different cut-off values according to the BMI: 62 and
392 ng/dL, respectively for non-obese and obese sub-
jects. Although all of our patients were overweight by
the inclusion criteria (BMI ≥ 25 kg/m2), the P80 cut-
off value of 47 ng/dL for post-DST saliva cortisol was
way below that proposed by Castro in the non-obese
(28), presumably increasing test sensitivity.
Table 4. Clinical and laboratory data of eight patients with likely “endogenous hypercortisolism”, investigated for Cushing’s syndrome.
ID Sex/ Years BMI Waist WHR ↑ BP HbA1c Cortisol ACTH DHEAS FU DDAVP Adrenal Pituitary
age of DM CT MR
Saliva Saliva Serum Serum
23:00 1 mg 1 mg 2 mg
A F 36 5 32.3 98 1.04 Yes 7.0 264 20.1 2.7 * 12.0 162 65 - Nl Nl
B F 43 11 29.6 94 0.92 Yes 14.4 371 48.7 2.1 0.9 28.3 97 50 + BAH+ Nl
Nodule
C F 56 6 33.1 100 1.00 Yes 7.8 283 27 2.7 1 13.7 40 73 - Nl Nl
D F 67 34 36.0 113 0.89 Yes 6.8 391 117 4.7 2.6 8.6 11 172 - BAH Empty 
sella
E M 48 8 27.1 98 1.01 No 6.2 527 66.5 1.6 0.9 15.0 15 183 - BAH Nl
F M 55 6 38.1 124 0.95 Yes 6.2 370 98 7.8 0.7 36.6 67 75 - Nl Nl
G M 59 10 28.1 102 1.02 Yes 7.3 346 50 1.9 0.3 7.9 122 64 - Nl Nl
H M 62 1 25.5 91 0.92 No 6.3 386 83.4 1.3 0.9 12.8 178 82 + BAH 6 mm
nodule 
* Invalid test
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Because the cut-off value for post-DST serum
cortisol (considered our gold-standard test) was
already highly sensitive (1.8 µg/dL), in accordance
with that for the post-DST saliva cortisol (47 ng/dL),
individual pairs of post-DST serum and saliva cortisol,
which correlate positive and significantly, were con-
cordant in 82.4% of the validated tests.
From the 29 out of the 103 original patients
(28%), six declined further investigation. Also, from
the remaining 23 patients (22%), 15 who had previ-
ously normal 23:00 h saliva cortisol levels had their
investigation terminated since responded normally to a
confirmatory 2 mg x 2 d DST.
Thus, further detailed investigation was con-
ducted only in the eight remaining patients who had
at least two positive test results. When compared to
patients who had normal responses to all tests and
those with only one abnormal result, these eight
patients did not disclose any particular clinical differ-
ence, except for being more hypertensive than the first
group. Both serum glucose and HbA1c levels were
similar, if not lower, than the other two groups. As
expected for what is considered unsuspected or subclin-
ical disease, only hormonal testing was abnormal (32-
34).
Five of these eight patients were subsequently
excluded due to normal ACTH, urinary free cortisol,
serum DHEAS, and DDAVP stimulation test. Also
adrenal and pituitary imaging were unremarkable. The
final three patients (# B, D, and H, in table 4) were
defined as subclinical CS. Because surgery or pharma-
cologic adrenalectomy was not attempted in any of
them, we were able to follow them critically for the past
two years. In none clinical manifestations of Cushing’s
syndrome ever became evident. In adrenal incidentalo-
mas, progression of subclinical to overt CS is question-
able, but probably occurs only occasionally (35).
Each patient from the original series who had
only one abnormal test response was tentatively con-
sidered a false-positive for that test. In previous publi-
cations, functional abnormalities in the hypothalamic-
pituitary-adrenal (HPA) axis were vaguely associated
to the presence of obesity (36), hypertension (37), and
diabetes mellitus (37,38). Most of these features were
present in over 70% of our patients, and could easily
explain some of the false-positive values, even in those
who had two abnormal test results but in whom both
adrenal and pituitary imaging were unrevealing.
However, this is still contradictory and open to
discussion. We have previously demonstrated that obe-
sity is not a cause of false-positive results for the 1 mg
overnight DST, although a cut-off level of 5 µg/dL
was used at that time to define cortisol suppressibility
(39). Others have found similar results (40). In the
present study we also corroborate previous results (6)
in that poorly-controlled diabetes may not make
patients more prone to biochemical abnormalities in
the HPA axis. Possible correlations between HbA1c
levels or the presence of hypertension with the
responses to each of the tests used were lacking in our
study.
In addition, we have attempted to exclude false-
positive results in response to the DST by measuring
serum dexamethasone levels. A serum concentration
greater than 157 ng/dL was required for proper vali-
dation of the test. Similar results (220 ng/dL) were
reported by others (41).
Absence of the circadian cortisol rhythm is gen-
erally considered the weakest among the screening
tests for CS (42). This is due to the fact that several
diseases and/or clinical conditions may be associated
with a lack of cortisol decay towards the evening, in
special depressive disorders (in whom the response to
DST may also be positive), aging, and the presence of
hypertension and/or diabetes (37). However, late-
night salivary cortisol levels were reasonably sensitive
and specific (92% and 93%, respectively) in discrimi-
nating patients with CS, from pseudo-CS, obese and
non-obese control subjects (43). Also, in a recent
review, Findling and Raff (44) suggest that 23:00 h
salivary cortisol, drawn in two different occasions, may
be the best approach to screen patients for CS.
In reported series of patients with an adrenal
incidentaloma and subclinical CS, the absence of clin-
ical manifestations is justified by normal cortisol pro-
duction rates (35). This can be reflected by the normal
24h-urinary free cortisol levels observed in our
patients.
Finally, taken altogether the results of the pre-
sent study were very suggestive, although not confir-
matory, that the prevalence of CS, in its subclinical
form, is significantly higher in populations at risk for
the disorder than in the general population, as previ-
ously observed by Leibowitz et al. (5) and Catargi et
al. (6). Although current recommendations advise that
only poorly controlled diabetic patients should be
investigated for subclinical CS, two out of our three
most distinctive candidates for this diagnosis had rea-
sonably controlled DM2.
It is also worth to mention that although sub-
clinical CS is typical of patients with an adrenal inci-
dentaloma, hypothalamic-pituitary disease may also be
found incidentally, as possibly suggested in two of our
patients.
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